Pharmaceutical manufacturers of Latanoprost

Founded in 1978, Biocon Limited is the largest biotechnology company in India and a leading company in Asia, focusing on biopharmaceuticals and research services. It is an integrated and innovation-driven enterprise that provides affordable solutions for chronic diseases globally. The company develops, manufactures, and offers a diverse portfolio of Small Molecules APIs & Formulations and Complex Biologics, including Novels and Biosimilars like MAbs, rh-insulin& Insulin Analogs. Among its notable products are the world's first Pichia-based recombinant human Insulin, INSUGEN, Glargine, BASALOG, and India's first biologic BioMAb-EGFR for head and neck cancer. Additionally, it has developed Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, introduced as Alzumab for psoriasis in India in 2013.

Teva's roots are deeply rooted in the land of Israel since 1901 in Jerusalem. That's when the first chapter was written in the long and unique history of the company, which slowly transformed from a small drug trading house to the largest generic company in the world, improving the health of millions of patients in Israel and around the world every day.

Pfizer CentreOne® is a completely distinct global contract development and manufacturing organization (CDMO), as well as a prominent provider of specialty APIs and intermediates. Supported by resources from Pfizer, we have provided technical knowledge, regulatory assistance, and long-term supply for more than 40 years. With a network of over 35 sites spanning six continents, we are capable of securely and effectively guiding complex compounds from development to commercial manufacture. For more details, please visit http://www.pfizercentreone.com

Euroapi focuses on revolutionizing active component solutions to sustainably fulfill the demands of clients and patients globally. As a prominent figure in active pharmaceutical ingredients, we possess a comprehensive portfolio of around 200 products, encompassing a wide range of technologies, and are constantly developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO). Our 3,350 employees are driven by the commitment to improving access to essential therapies and promoting health

In just over a decade, Laurus has positioned itself as one of the largest and most innovative API producers globally. Expanding upon its established expertise in chemistry, Laurus has recently adopted full vertical integration, including a strong finished dosage capacity, dedicated capacity for backward integration, and also Synthesis R&D operations in India and the USA.

Committed to excellence, scientific quality, and exceptional client engagement, Patheon is a prominent global supplier of contractual drug development and manufacturing services. With eight centers of excellence for development and thirteen manufacturing facilities spanning North America and Europe, Patheon offers pharmaceutical and biotechnology firms direct access to expertise, quality, and a full range of solid and sterile dosage forms to advance drug candidates from preclinical stages through production, and to introduce products globally.

We are utilizing the world's top-level fermentation and synthesis technologies to supply domestic and overseas users with various fine chemical products centered on amino and nucleic acids for pharmaceuticals, nutritional supplements, and industrial use, as well as the derivatives of such acids. Through the rapid progress in genome analysis seen in recent years, we anticipate the development of new biotechnology processes and products from fermentation, a technology which humankind has been utilizing since time immemorial.

Haorui, established in the year 1997, operates as a manufacturer and provider of APIs, pharmaceutical intermediates, veterinary products, and food additives. Furthermore, it aids international pharmaceutical firms in achieving domestic registration for their finished dosage forms to support their global expansion efforts. The company's array of USFDA approved products includes Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, and Dasatinib Monohydrate among others. Its headquarters is situated in Shenzhen, China, while it maintains four manufacturing sites in Hubei, Zhejiang, Jiangxi, and Henan. The Hubei facility is recognized for its USFDA and EU GMP approvals, specializing in the production of high potency and oncology materials within a dedicated oncology workshop, meeting OEB 5 material production standards. Haorui prides itself as a dependable partner for all your pharmaceutical needs.

Sai Life Sciences provides advanced Discovery, Contract Development and Manufacturing Solutions, utilizing a wide range of expert capabilities throughout the molecular lifecycle. At Sai Life Sciences, we offer scientific knowledge with a greater mission – to influence the future of healthcare by developing treatments for current incurable ailments. We collaborate with pioneering pharmaceutical and biotech firms to expedite the exploration, creation, and production of intricate small molecules for a healthier future. Our goal is to assist our global innovator partners in bringing 25 new medicines to life by 2025. And we are making significant progress towards that objective.

We are a pharmaceutical business based in India, specializing in active pharmaceutical ingredients (APIs) such as peptides and finished formulation drugs.

A trusted Indian pharmaceutical company with strong people and technology capabilities, providing affordable, high-quality products that meet the healthcare needs of people across the globe.

Established in the year 1991, SM Biomed Sdn. Bhd. is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates based out in Malaysia With our state-of-the-art manufacturing facility certified by USFDA, EDQM, EUGMP and NPRA (Malaysia), we are dedicated to improve the quality of life through developing and delivering innovative solutions and products at an affordable cost. With a legacy spanning more than three decades and pioneers for Macrolide based antibiotics, we work with customers globally with speed, efficiency and cost effective manufacturing capabilities. SM Biomed has grown as a market leader in Macrolides antibiotics and evolved into a knowledge driven company providing reliable pharmaceutical services including developing and manufacturing APIs and Intermediates. From pipeline to production, we make innovative, quality driven and customised products more accessible. We are a quality driven and R&D focused API manufacturing company with a diverse product portfolio catering various therapeutic segments.

Kimia Biosciences, established in 1993, specializes in the production of bulk drugs for various medical segments. With a strong focus on quality and advanced technologies, Kimia aims to achieve global recognition in the production of both APIs and FDFs, while maintaining ethical business practices. The state-of-the-art facilities at Village Bhondsi, Gurugram enable the production of a wide range of APIs. Additionally, Kimia plans to develop its own facilities for lifestyle segments, adhering to international regulatory standards, with the goal of delivering top-quality pharmaceutical products and support to both consumers and healthcare professionals.

DONGWHA PHARM, the earliest established pharmaceutical corporation in Korea established in 1897, has been involved in the advancement, manufacturing, distribution, and promotion of ethical medications such as solid dosage forms and sterile injectables, APIs, non-prescription drugs, dietary supplements, health products, and beauty products

With over three decades of experience, Gentec Pharmaceutical Group has established itself as a key player in the raw materials and components for the food, dietary, and nutrition industries. It produces and markets over 200 active pharmaceutical ingredients and offers a diverse range of finished goods. Gentec provides development and manufacturing services for APIs and intermediates, including HPAPIs at its Duke Chem and Pharmanoid facilities. Additionally, it delivers a broad spectrum of supplementary services encompassing regulatory and legal aspects, such as permits for product formulation and market evaluation.

C2 PHARMA, founded in 2014, is a pharmaceutical conglomerate that specializes in the production and distribution of active pharmaceutical ingredients (APIs) and intricate chemical compounds derived from both natural and synthetic sources. Its current API product line encompasses atropine, bimatoprost, brimonidine, cyclopentolate, digoxin, homatropine, latanoprost, pilocarpine, and tropicamide, and has a global reach extending to over 200 pharmaceutical firms in the United States, Western and Eastern Europe, South America, Asia, the Middle East, and Africa. C2 PHARMA also delivers personalized cold-chain logistics solutions through its dedicated subsidiary, Logistics4Pharma (logistics4pharma.com), and provides R&D-scale contract synthesis services, analytical services, phytochemical profiling, and impurities manufacturing via its associate ASM Research Chemicals (asm-research.de). Notably, C2 PHARMA is a significant supporter of the “Partnerships for a Better World” initiative, which ensures the sustainable, traceable, and equitable procurement and harvesting of raw materials for API production, particularly pilocarpine. This initiative sustains over 1,000 families and contributes to the preservation of Brazilian biodiversity.

Everlight Chemical Industrial Co. established in 1972 commenced the development of prostaglandin APIs in 1992. We have attained sustainable expansion through the equilibrium of financial, societal, and environmental accountability as well as ensuring worker's safety. Our APIs have been officially recognized globally, encompassing the US, Canada, UK, EU, Japan, China, Russia, India, South America, Egypt, the Middle East, and more. Our facility holds certifications from the Taiwan FDA, US FDA, EMEA, PMDA, and Swedish MPA. Presently, our sales reach over 40 countries worldwide.